Iovance Biotherapeutics, Inc. (IOVA:NASDAQ) closed at $13.78 on October 26, 2026, down 2.20% on the day. The stock trades 10.3% below its 52-week high of $15.37 and 683.0% above its 52-week low of $1.76. Over the past year, it gained 526.2%. Iovance Biotherapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 24, 2025, IOVA closed higher on 119 days (47%). Its best day was August 6, 2026 (+43.09%) and its worst was March 12, 2026 (-15.91%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 6 times.
Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufactu...
Find more stocks like IOVA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.